|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry and western blot were conducted to determine the RAB1A expression in CRC tissues and cells, respectively.
|
31598673 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, this study suggested that circ_0000218 up-regulated RAB1A and promoted CRC proliferation and metastasis via sponging miR-139-3p.
|
31598673 |
2020 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, we first demonstrated that Rab1A was overexpressed in CRC tissues and Rab1A overexpression was positively related to lymph node invasion, degree of differentiation, venous invasion and tumor‑node‑metastasis (TNM) stage.
|
30896866 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.
|
31527621 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of Rab1A was closely related to the tumor size and the depth of tumor invasion.
|
31038077 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Final pathologic tumor category (AJCC eighth edition) was 46.9% ypT1, 34.4% ypT2, and 18.7% ypT3.
|
30211728 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The level of p‑S6K1 was markedly high in CRC tissues and Rab1A expression level had a positive association with p‑S6K1 level.
|
30896866 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We detected significantly higher expression of Rab1A in the gastrointestinal tumor tissues compared to that in other cancer types following an in silico analysis of TGCA and GTEX databases.
|
31527621 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings indicate that Rab1A plays an important role in CRC and may provide a therapeutic target for CRC, particularly for mTORC1‑targeted therapy‑resistant cancers.
|
30896866 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Patients with rectal cancer staged ypT4N0 were associated with higher locoregional recurrence and distant metastasis rates than those staged ypT1-2N1 in the current staging system.
|
30595556 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
|
30896866 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC) was performed to explore the association of Rab1A/p-S6K/Gli1 expression and prognosis in 117 GC tissue samples and adjacent normal tissues.
|
31038077 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, Rab1A regulates the PI3K-AKT-mTORC1 pathway through the mTORC1 complex consisting of mTORC1, Rheb and Rab1A, and is a promising therapeutic target in GC.
|
31527621 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC) was performed to explore the association of Rab1A/p-S6K/Gli1 expression and prognosis in 117 GC tissue samples and adjacent normal tissues.
|
31038077 |
2019 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, Rab1A regulates the PI3K-AKT-mTORC1 pathway through the mTORC1 complex consisting of mTORC1, Rheb and Rab1A, and is a promising therapeutic target in GC.
|
31527621 |
2019 |